'Real-World' antithrombotic treatment in atrial fibrillation: The eorp-af pilot survey

American Journal of Medicine

Volumn 127, Issue 6, 2014, Pages

  Lip, Gregory Y H ^a   Laroche, Cécile ^b   Dan, Gheorghe Andrei ^c   Santini, Massimo ^d   Kalarus, Zbigniew ^e   Rasmussen, Lars Hvilsted ^f,g   Ioachim, Popescu Mircea ^h   Tica, Otilia ^h   Boriani, Giuseppe ⁱ   Cimaglia, Paolo ⁱ   Diemberger, Igor ⁱ   Hellum, Camilla Fragtrup ^f,g   Mortensen, Bettina ^f,g   Maggioni, Aldo P ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b European Society of Cardiology   (France)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d SAN FILIPPO NERI HOSPITAL   (Italy)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g AALBORG UNIVERSITY   (Denmark)

^h University of Oradea   (Romania)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atrial fibrillation; Bleeding; Oral anticoagulation; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K;

ADULT; AGED; ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PILOT STUDY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; VALVULAR HEART DISEASE;

ATRIAL FIBRILLATION; BLEEDING; ORAL ANTICOAGULATION; STROKE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; RISK FACTORS; STROKE;

EID: 84899629696     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.12.022     Document Type: Article

References (37)

1. A. Banerjee, F. Marin, and G.Y. Lip The improved but unfinished business of stroke risk stratification in atrial fibrillation Rev Esp Cardiol 64 2011 639 641
2. R. Nieuwlaat, A. Capucci, and G.Y. Lip et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on atrial fibrillation Eur Heart J 27 2006 3018 3026 (Pubitemid 44963431)
3. A.J. Camm, G.Y. Lip, and R. De Caterina et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association Europace 14 2012 1385 1413
4. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation Chest 137 2010 263 272
5. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
6. J. Kornej, T. Potpara, and G.Y. Lip Anticoagulation management in non-valvular atrial fibrillation: current and future directions Pol Arch Med Wewn 123 11 2013 623 634
7. S. Ogawa, K. Aonuma, and H.F. Tse et al. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation J Arrhythmia 29 2013 190 200
8. J.J. You, D.E. Singer, and P.A. Howard et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines Chest 141 2012 e531S e575S
9. A. Skanes, J. Healey, and J. Cairns et al. Focused 2012 update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: recommendations for stroke prevention and rate/rhythm control Can J Cardiol 28 2012 125 136
10. V. Fuster, L.E. Ryden, and D.S. Cannom et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society J Am Coll Cardiol 57 2011 e101 e198
11. G.Y. Lip, C. Laroche, and G.A. Dan et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry Europace 2013 Dec 17 [Epub ahead of print]
12. Stroke-in-AF-Working-Group Independent predictors of stroke in patients with atrial fibrillation: a systematic review Neurology 69 2007 546 554
13. L. Friberg, M. Rosenqvist, and G.Y. Lip Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study Eur Heart J 33 2012 1500 1510
14. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials Arch Intern Med 158 1998 1316 1320
15. A. Banerjee, S. Taillandier, and J.B. Olesen et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project Eur J Heart Fail 14 2012 295 301
16. B. Anandasundaram, D.A. Lane, S. Apostolakis, and G.Y. Lip The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review J Thromb Haemost 11 2013 975 987
17. G.Y. Lip Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation BMJ 336 2008 614 615 (Pubitemid 351439522)
18. F. Marin, K. Huber, and G.Y. Lip Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy Thromb Haemost 110 2013 623 625
19. A. Bernard, L. Fauchier, and C. Pellegrin et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation Thromb Haemost 110 2013 560 568
20. W.J. Dewilde, T. Oirbans, and F.W. Verheugt et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115
21. R. Marinigh, D.A. Lane, and G.Y. Lip Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk J Am Coll Cardiol 57 2011 1339 1348
22. V. Roldán, F. Marin, and S. Manzano-Fernandez et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 109 2013 956 960
23. J.B. Olesen, G.Y. Lip, and A.L. Kamper et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease N Engl J Med 367 2012 625 635
24. R.G. Hart, L.A. Pearce, R.M. Rothbart, J.H. McAnulty, R.W. Asinger, and J.L. Halperin Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators J Am Coll Cardiol 35 2000 183 187 (Pubitemid 30061278)
25. R. Nieuwlaat, T. Dinh, and S.B. Olsson et al. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J 29 2008 915 922 (Pubitemid 351499500)
26. J. Mant, F.D. Hobbs, and K. Fletcher et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial Lancet 370 2007 493 503 (Pubitemid 47212371)
27. A. Rash, T. Downes, R. Portner, W.W. Yeo, N. Morgan, and K.S. Channer A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO) Age Ageing 36 2007 151 156 (Pubitemid 46455393)
28. G.Y. Lip The role of aspirin for stroke prevention in atrial fibrillation Nat Rev Cardiol 8 2011 602 606
29. T. Wilke, A. Groth, and S. Mueller et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients Thromb Haemost 107 2012 1053 1065
30. P. Kirchhof, B. Ammentorp, and H. Darius et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF) Europace 16 2014 6 14
31. G.Y. Lip Recommendations for thromboprophylaxis in the 2012 focused update of the ESC Guidelines on Atrial Fibrillation: a commentary J Thromb Haemost 11 2013 615 626
32. R. De Caterina, S. Husted, and L. Wallentin et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease Thromb Haemost 110 2013 1087 1107
33. K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch Intern Med 172 2012 397 402
34. J.W. Eikelboom, S.J. Connolly, and M. Brueckmann et al. Dabigatran versus warfarin in patients with mechanical heart valves N Engl J Med 369 2013 1206 1214
35. A. Banerjee, D.A. Lane, C. Torp-Pedersen, and G.Y. Lip Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study Thromb Haemost 107 2012 584 589
36. R. Pisters, R. Nieuwlaat, D.A. Lane, H.J. Crijns, and G.Y. Lip Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey Thromb Haemost 109 2013 328 336
37. P. Gallego, V. Roldan, and F. Marin et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation Thromb Haemost 110 2013 1189 1198